BiRd (clarithromycin, lenalidomide, dexamethasone): An update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma

Blood

Volumn 121, Issue 11, 2013, Pages 1982-1985

  Rossi, Adriana ^a   Mark, Tomer ^a   Jayabalan, David ^a,b   Christos, Paul ^b   Zafar, Faiza ^a   Pekle, Karen ^a   Pearse, Roger ^a   Chen Kiang, Selina ^b   Coleman, Morton ^a   Niesvizky, Ruben ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLARITHROMYCIN; COTRIMOXAZOLE; DEXAMETHASONE; LENALIDOMIDE; OMEPRAZOLE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; THALIDOMIDE;

ARTICLE; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SECOND CANCER; TREATMENT RESPONSE; ADJUVANT THERAPY; AUTOTRANSPLANTATION; EVALUATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METHODOLOGY; MORTALITY; PHASE 2 CLINICAL TRIAL (TOPIC); RETROSPECTIVE STUDY; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLARITHROMYCIN; CLINICAL TRIALS, PHASE II AS TOPIC; DEXAMETHASONE; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MAINTENANCE CHEMOTHERAPY; MALE; MULTIPLE MYELOMA; NEOADJUVANT THERAPY; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS;

MLCS; MLOWN;

EID: 84877620340     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-08-448563     Document Type: Article

References (14)

1. Weber DM, Chen C, Niesvizky R, et al; Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007; 357(21):2133-2142.
2. Dimopoulos M, Spencer A, Attal M, et al; Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma [published correction appears in N Engl J Med. 2009;361(5):544]. N Engl J Med. 2007;357(21):2123-2132.
3. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005;106(13):4050-4053.
4. Niesvizky R, Jayabalan DS, Christos PJ, et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood. 2008;111(3): 1101-1109.
5. Gay F, Rajkumar SV, Coleman M, et al. Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. Am J Hematol. 2010;85(9):664-669.
6. Niesvizky R, Bergsagel PL, Pearse RN, et al. Clarithromycin potentiates the response to dexamethasone in chemotherapy naïve multiple myeloma patients: a prospective sequential, randomized trial [abstract]. Blood. 2002;100:389b.
7. Mark T, Stern J, Furst JR, et al. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant. 2008;14(7): 795-798.
8. Mark T, Jayabalan D, Coleman M, et al. Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. Br J Haematol. 2008;143(5): 654-660.
9. Rossi A, Mark T, Jayabalan D, et al. Incidence of second primary malignancies after 6 years followup of continuous lenalidomide in first-line treatment of multiple myeloma [abstract]. J Clin Oncol. 2011;29(suppl):Abstract 8008.
10. Attal M, Lauwers-Cances V, Marit G, et al; IFM Investigators. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma N Engl J Med. 2012;366(19):1782-1791.
11. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19): 1770-1781.
12. Palumbo A, Hajek R, Delforge M, et al; MM-015 Investigators. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759-1769.
13. Durie BG, Harousseau JL, Miguel JS, et al; International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473.
14. Dimopoulos MA, Richardson PG, Brandenburg N, et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood. 2012; 119(12):2764-2767.